Piper discusses potential takeout candidates after Amylin

theflyonthewall.com

Piper Jaffray highlights BioMarin (BMRN), Affymax (AFFY), Theravance (THRX), and Rigel Pharmaceuticals (RIGL) as potential takeout candidates in the biotech space following Bristol-Myers' (BMY) acquisition of Amylin (AMLN). Piper believes an acquisition of BioMarin could be valued at $79 per share, and says Takeda could be the most likely suitor for Affymax.

View Comments (0)